EPS for GlaxoSmithKline plc (GSK) Expected At $0.64; UNI PIXEL (UNXLQ) Shorts Up By 9.73%

January 13, 2018 - By Dolores Ford

Analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.64 EPS on February, 14.They anticipate $0.01 EPS change or 1.54% from last quarter’s $0.65 EPS. GSK’s profit would be $1.49B giving it 14.65 P/E if the $0.64 EPS is correct. After having $0.85 EPS previously, GlaxoSmithKline plc’s analysts see -24.71% EPS growth. The stock increased 1.79% or $0.66 during the last trading session, reaching $37.5. About 5.00M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since January 13, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

UNI PIXEL INCORPORATED (OTCMKTS:UNXLQ) had an increase of 9.73% in short interest. UNXLQ’s SI was 238,000 shares in January as released by FINRA. Its up 9.73% from 216,900 shares previously. With 467,900 avg volume, 1 days are for UNI PIXEL INCORPORATED (OTCMKTS:UNXLQ)’s short sellers to cover UNXLQ’s short positions. The stock decreased 17.27% or $0.0019 during the last trading session, reaching $0.0091. About 391,497 shares traded or 58.67% up from the average. Uni-Pixel, Inc. (OTCMKTS:UNXLQ) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 17 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 1 Sell and 9 Hold. Therefore 41% are positive. GlaxoSmithKline had 26 analyst reports since September 8, 2015 according to SRatingsIntel. Argus Research maintained GlaxoSmithKline plc (NYSE:GSK) rating on Friday, August 12. Argus Research has “Buy” rating and $50 target. The rating was upgraded by BNP Paribas to “Neutral” on Wednesday, April 5. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Overweight” rating given on Friday, September 23 by Piperjaffray. The firm has “Underweight” rating given on Friday, September 8 by Morgan Stanley. Bryan Garnier & Cie upgraded the shares of GSK in report on Wednesday, January 27 to “Buy” rating. The rating was downgraded by Citigroup on Wednesday, July 5 to “Neutral”. Bank of America upgraded GlaxoSmithKline plc (NYSE:GSK) on Tuesday, September 8 to “Neutral” rating. Argus Research maintained it with “Buy” rating and $48 target in Monday, December 7 report. Bank of America downgraded the stock to “Hold” rating in Thursday, October 26 report. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Underperform” rating given on Wednesday, September 14 by BNP Paribas.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of $87.55 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 29.25 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Uni-Pixel, Inc. designs, develops, manufactures, and markets micro-structured polymer film materials and related technologies for the display, flexible electronics, and automotive industries in the United States. The company has market cap of $666,216. The firm markets its touch screen films as sub-components of a touch sensor module under the XTouch brand; and hard coat resin and optical films under the Diamond Guard brand. It currently has negative earnings. Uni-Pixel, Inc. was founded in 1998 and is headquartered in Santa Clara, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts